Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Lenvima“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · 19 Description of selected adverse reactions
Eintrag öffnenLenvima · 4.8 · 20 Renal failure and impairment (see section 4.4)
Eintrag öffnenLenvima · 4.8 · 21 Amongst 1,823 patients treated with lenvatinib monotherapy in clinical trials, there were 5 cases (0.3%) of
Eintrag öffnenLenvima · 4.8 · 22 Arterial thromboembolisms (see section 4.4)
Eintrag öffnenLenvima · 4.8 · 24 from two weeks to greater than 1 year from initiation of lenvatinib, with median latency of about 3 months.
Eintrag öffnenLenvima · 4.8 · 26 In Study 231, the most frequently reported (≥15%) adverse drug reactions were hypothyroidism, hypertension,
Eintrag öffnenLenvima · 4.8 · 28 Reporting of suspected adverse reactions
Eintrag öffnenLenvima · 4.8 · Across clinical trials in which 1,327 patients received lenvatinib monotherapy in indications other than HCC,
Eintrag öffnenLenvima · 4.8 · Across clinical trials in which 1327 patients received lenvatinib monotherapy in indications other than HCC, h
Eintrag öffnenLenvima · 4.8 · Adverse reactions observed in clinical trials in DTC, HCC, and EC, and reported from post-marketing use of len
Eintrag öffnenLenvima · 4.8 · Amongst 1,166 patients treated with lenvatinib, there were 3 cases (0.3%) of hepatic failure, all with a fatal
Eintrag öffnenLenvima · 4.8 · Amongst 1,823 patients treated with lenvatinib monotherapy in clinical trials, there were 10 cases (0.5%) of a
Eintrag öffnenLenvima · 4.8 · Asian patients had a higher (≥ 10% difference) incidence than Caucasian patients of peripheral oedema, hyperte
Eintrag öffnenLenvima · 4.8 · Asian patients had a higher (≥10% difference) incidence than Caucasian patients of anaemia, malaise, neutrophi
Eintrag öffnenLenvima · 4.8 · Asian patients had a higher incidence than Caucasian patients of proteinuria, decreased neutrophil count, decr
Eintrag öffnenLenvima · 4.8 · Baseline hypertension
Eintrag öffnenLenvima · 4.8 · Blood TSH increased was reported in 12.8% of lenvatinib plus pembrolizumab-treated patients with no patients r
Eintrag öffnenLenvima · 4.8 · Cardiac dysfunction (see section 4.4)
Eintrag öffnenLenvima · 4.8 · Diarrhoea (see section 4.4)
Eintrag öffnenLenvima · 4.8 · Discontinuation of lenvatinib occurred in 30.6% of patients, and discontinuation of both lenvatinib and pembro
Eintrag öffnen